← Back to Search

Fundus autofluorescence (FAF) imaging for Age-Related Macular Degeneration (FPF in AMD Trial)

N/A

Recruiting

Led By Mihai Mititelu, MD, MPH

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Established diagnosis of GA due to AMD

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 45 minutes

Awards & highlights

FPF in AMD Trial Summary

This trial aims to see if stressed cells in the retina match up with areas of disease seen in standard imaging and if these images can help identify potential problem areas before symptoms appear. The main focus is on

Who is the study for?

This trial is for individuals with Age-Related Macular Degeneration (AMD), a condition affecting the retina. It's designed to see if stressed cells in the retina show up in specific imaging before symptoms appear or the disease progresses.Check my eligibility

What is being tested?

The study tests how well FPF imaging using OcuMet Beacon can detect areas of retinal cell stress and potential early signs of AMD progression, compared to standard imaging techniques.See study design

What are the potential side effects?

Since this trial involves non-invasive retinal imaging, there are minimal side effects expected. Participants may experience discomfort from bright lights during the imaging process.

FPF in AMD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with geographic atrophy due to age-related macular degeneration.

FPF in AMD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 45 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 45 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 45 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Limits of agreement between the fundus autofluorescence (FAF) area of GA images taken with the Heidelberg Spectralis to the flavoprotein fluorescence (FPF) area of GA with images taken with the OcuMet Beacon

Secondary outcome measures

Compare the cross-sectional associations between FPF intensity (average pixel intensity over a 5.5 mm-diameter region centered at the macula) to FAF area at the time of measurement

Compare the cross-sectional associations between best corrected visual acuity (BCVA - using Early Treatment Diabetic Retinopathy Study, greater number of letters read correctly equals better vision) to FAF area at the time of measurement

FPF in AMD Trial Design

1Treatment groups

Experimental Treatment

Group I: Fundus autofluorescence (FAF) imagingExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor

1,192 Previous Clinical Trials

3,161,987 Total Patients Enrolled

Mihai Mititelu, MD, MPHPrincipal InvestigatorUniversity of Wisconsin, Madison

1 Previous Clinical Trials

46 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals able to enroll in this study at the moment?

"As per clinicaltrials.gov, the ongoing trial is not currently seeking volunteers. This study was initially listed on April 1st, 2024 and last updated on April 19th, 2024. Although this particular trial isn't enrolling participants now, there are a total of 172 other trials actively recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

2024. "Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06381596.